

## TORCH INFECTIONS DIAGNOSIS AND TREATMENT METHODS OF TOXOPLASMOSIS

**Ra‘no Sh. Boltayeva<sup>1</sup>, Nargiza Q. G‘ulomjonova<sup>2</sup>,  
Boburjon Z. Tursunov<sup>3</sup>, Hamidaxon O. Ismatullayeva<sup>4</sup>**

**1** Assistant of the Department of Microbiology, Virology, Immunology,  
Tashkent Medical Academy, Tashkent, Uzbekistan  
E-mail: guliranoboltayeva@gmail.com

**2** Student of the Tashkent Medical Academy, Tashkent, Uzbekistan  
E-mail: gulomjonovanargiza90@gmail.com

**3** Student of the Tashkent Medical Academy, Tashkent, Uzbekistan

**4** Student of the Tashkent Medical Academy, Tashkent, Uzbekistan

### ABSTRACT

TORCH infections refer to a group of interrelated infectious diseases that pose significant risks during pregnancy, among which toxoplasmosis holds particular importance. Toxoplasmosis is an infection caused by the *Toxoplasma gondii* parasite, primarily transmitted from animals to humans. This article discusses modern diagnostic methods used to identify toxoplasmosis, the risks it poses during pregnancy, and the importance of timely treatment. Detailed information is provided on serological tests, PCR methods, and other diagnostic approaches. Furthermore, treatment options, including the efficacy of antibiotics and antiparasitic drugs, are analyzed. The article reviews clinical recommendations, preventive measures, and the necessity of early diagnosis during pregnancy. The presented information aims to equip readers with the knowledge and approaches needed to reduce the impact of toxoplasmosis and combat it effectively.

**Key words:** TORCH infections, toxoplasmosis, *Toxoplasma gondii*, diagnosis, serological tests, PCR, pregnancy, antiparasitic treatment, prevention, infectious diseases, treatment methods, diagnostic techniques.

### INTRODUCTION

TORCH infections (Toxoplasmosis, Other infections, Rubella, Cytomegalovirus, Herpes simplex virus) are a group of infections that pose serious risks to both the mother and fetus during pregnancy. These infections manifest in various clinical forms, with toxoplasmosis being one of the most widespread and

significant diseases [20]. Toxoplasmosis, caused by the *Toxoplasma gondii* parasite, is primarily transmitted from animals to humans. This article provides comprehensive information on the diagnosis and treatment of toxoplasmosis, along with its risks during pregnancy. It also emphasizes the importance of early detection and prevention [33].

In the past decade, scientific and clinical studies on toxoplasmosis have seen significant advancements. Researchers have focused on better understanding the pathogenesis of toxoplasmosis, improving treatment methods, enhancing diagnostic techniques, and refining prevention strategies. Below is an analysis of key studies and breakthroughs during this period.

### **Etiology and Transmission of Toxoplasmosis**

Toxoplasmosis is an infection caused by the *Toxoplasma gondii* parasite, commonly transmitted to humans through animals, particularly cats. Cats serve as the primary reservoir for *Toxoplasma gondii*, spreading the parasite via their urine and feces [35]. The main transmission routes to humans include:

Contaminated food (especially raw or undercooked meat, unwashed fruits, and vegetables). Direct contact with cat feces. Pregnant women infected with toxoplasmosis can transmit the infection to the fetus, leading to significant risks and complications. Studies have shown that the global prevalence of toxoplasmosis is increasing, particularly in developing countries where poor sanitation and epidemiological conditions heighten the risk of infection [27, 30].

### **Studies on Parasitic Biology and Pathogenesis**

Detailed research into the pathogenesis of *Toxoplasma gondii* continued over the last 10 years. Studies analyzing the parasite's genome and its activity, particularly the genetic information of *Toxoplasma gondii*, have contributed to the development of new therapies.

In 2014, researchers from New York University and the University of London uncovered new insights into the genome of *Toxoplasma gondii* and its interactions with the host organism. These studies helped elucidate how the parasite interacts intricately with host cells and how it produces critical hormones[30, 25, 28].

In 2019, researchers from Harvard University and Yale University studied how toxoplasmosis affects brain cells, confirming the link between parasitic infections and neurological diseases. Their findings showed that *Toxoplasma gondii* could cause persistent inflammation and neuronal death in affected brain regions, potentially linking it to neuropathologies and neurodegenerative diseases such as Parkinson's disease[29].

From 2023 to 2024, extensive research was conducted on the molecular basis of toxoplasma pathogenesis. Studies by researchers in the Middle East analyzed novel mutations in the *Toxoplasma gondii* genome and their mechanisms, uncovering how the parasite interacts with the immune system and affects host cells[14, 11].

A study published in Nature Communications in 2023 highlighted newly identified virulence factors of *Toxoplasma gondii* and provided insights into the parasite's mechanisms of interaction with host cells[10]. Moreover, the use of CRISPR technologies, which began in 2019, was expanded in 2023 to manipulate the parasite's genetics and study its effects on host cells. This approach paves the way for molecular-level treatment strategies for toxoplasmosis in the future[35, 25, 28].

### **Clinical Manifestations of Toxoplasmosis**

The clinical presentation of toxoplasmosis is highly variable. In most cases, the infection is asymptomatic or presents with mild flu-like symptoms, making it challenging to diagnose based on symptoms alone[8]. However, in individuals with weakened immune systems such as pregnant women, AIDS patients, or organ transplant recipients severe clinical forms of toxoplasmosis may occur[7].

During pregnancy, maternal infection can lead to transmission to the fetus, potentially resulting in: Developmental delays. Brain and eye inflammation. Congenital anomalies such as microcephaly, hydrocephalus, and chorioretinitis. Fetal death in severe cases[23, 9]. The prenatal form of toxoplasmosis is associated with significant perinatal complications, emphasizing the need for timely detection and management[22].

### **Diagnosis of Toxoplasmosis**

Toxoplasmosis diagnosis is carried out using serological and molecular methods:

#### **Serological Diagnosis:**

Immunoassays (ELISA) are widely used to detect IgM and IgG antibodies. IgM antibodies indicate a recent infection, while IgG suggests a past infection or established immunity[10]. Furthermore, the IgG avidity test helps determine the stage of the infection; high avidity IgG antibodies typically indicate an infection that occurred before pregnancy[14, 11].

PCR (Polymerase Chain Reaction): This method detects the genetic material (DNA) of the parasite and provides an accurate diagnosis of toxoplasmosis. PCR testing is especially critical for pregnant women, as it can determine whether the infection has been transmitted to the fetus[16].

## **Advances in Diagnostic Approaches**

Significant progress has also been made in toxoplasmosis diagnostics. The sensitivity and accuracy of serological tests and PCR (Polymerase Chain Reaction) methods have improved substantially over the last decade[25].

In 2016, a study in France introduced a new duplex-PCR method for the rapid diagnosis of toxoplasmosis. This approach allowed simultaneous detection of *Toxoplasma gondii* and similar pathogens like *Neospora caninum*. [28, 29].The technology has proven effective in agriculture, veterinary fields, and early diagnosis in humans[18].

In 2020, Japanese researchers identified a new biomarker for serological testing of toxoplasmosis. This marker significantly improved the sensitivity of IgM and IgG antibody detection, aiding in the rapid and precise diagnosis of toxoplasmosis. The adoption of advanced diagnostic methods, such as fluorescence immunoassay (FIA), has further enhanced the ability to diagnose and initiate treatment promptly[35, 25 28]

### **Diagnostics of Toxoplasmosis: New Technologies (2023-2024)**

In 2023, new diagnostic methods were introduced to improve early detection of toxoplasmosis. PCR-based rapid diagnostic systems were optimized for higher sensitivity and accuracy. These advancements enable the identification of infections in their early stages, facilitating timely treatment[23, 9].

Researchers from the University of Bern in Switzerland and the University of Paris collaborated in 2023 to develop a multiplex-PCR method. This technique can simultaneously detect multiple infections, such as toxoplasmosis and neosporosis, and is expected to benefit both veterinary and clinical practices[23].

Toxoplasmosis is an infectious disease caused primarily by the parasite *Toxoplasma gondii*, which poses a serious risk during pregnancy. The disease can present in mild or asymptomatic forms in many patients, but in pregnant women and individuals with weakened immune systems, the infection often leads to severe complications. The risk of toxoplasmosis during pregnancy affects not only the mother's health but also directly impacts the fetus, as the parasite can be transmitted to the unborn child, leading to severe neurological and organ-forming disorders such as microcephaly, hydrocephalus, and ocular inflammation.

The diagnosis of toxoplasmosis is carried out using modern laboratory techniques, with serological tests and PCR methods playing a key role. Serological tests are used to determine the timing of the infection, while PCR ensures high accuracy in detecting the genetic material of the parasite. These diagnostic methods enable early detection of the disease and provide an opportunity for prevention, especially in pregnant women, offering effective approaches to reduce

the potential health risks of toxoplasmosis. Additionally, modern treatment protocols have been developed to manage complications that may arise during the post-infection phase. Antiparasitic medications, such as pyrimethamine and sulfadiazine, play a crucial role in the treatment of the disease, although they should be used with caution during pregnancy. Therefore, the treatment plan for toxoplasmosis focuses not only on eradicating the infection but also on preventing complications in the pregnancy.

Preventive measures are the most important factor in reducing the spread of toxoplasmosis and ensuring no risk to pregnancy. Simple but effective preventive actions, such as avoiding contact with cat feces, properly cooking meat, and consuming clean and well-washed food, play a significant role in preventing the spread of toxoplasmosis. Early detection of toxoplasmosis in pregnant women and its proper treatment provide the opportunity to reduce complications during pregnancy and maintain the health of the baby.

#### **Other Methods:**

Imaging techniques, such as ultrasound and computed tomography (CT), can be used to detect eye and brain damage in suspected toxoplasmosis cases. In rare cases, brain biopsy may be performed, though this is usually reserved for severe complications[13].

#### **Treatment Methods for Toxoplasmosis**

The primary goal of toxoplasmosis treatment is to eliminate the parasite and prevent complications in the fetus[5].

**Antiparasitic Medications:** Pyrimethamine and sulfadiazine are commonly used drugs for treating toxoplasmosis. These medications are effective when used together. However, they deplete folate levels, so folic acid supplementation is required during treatment[1].

#### **Treatment Considerations:**

Treatment during pregnancy requires caution. Pyrimethamine is contraindicated in pregnancy, and alternative treatments like sulfadiazine and spiramycin are often used.[31] Spiramycin is effective in preventing the transmission of toxoplasmosis to the fetus. In cases where toxoplasmosis causes severe complications (e.g., brain inflammation), intensive treatment regimens may be necessary[32].

#### **Duration of Treatment:**

The treatment course for toxoplasmosis typically lasts 4–6 weeks, depending on the severity of the infection. Regular serological tests and PCR analyses are necessary to evaluate the effectiveness of the treatment[16].

Between 2023 and 2024, new drugs and treatment regimens for toxoplasmosis were developed. Alongside traditional medications such as sulfadiazine and pyrimethamine, research in 2023 investigated the efficacy of a new antibacterial drug, atovaquone. Studies showed that atovaquone is particularly effective in treating toxoplasmosis in immunocompromised patients[6].

These advancements represent significant progress in the prevention, diagnosis, and treatment of toxoplasmosis, offering promising solutions for managing the disease more effectively in the coming years[27, 30].

In 2020, with the support of global pharmaceutical companies, a new vaccine against toxoplasmosis was developed. While still in the clinical trial phase, the vaccine is expected to play a significant role in preventing toxoplasmosis in the future[29].

### **Risks of Toxoplasmosis During Pregnancy**

The risks of toxoplasmosis during pregnancy are linked to the gestational age of the fetus. Early-stage infections can lead to severe complications such as microcephaly, vision loss, and other neurological disorders. If toxoplasmosis develops during the last trimester, the infection is more likely to affect the fetus with symptoms but can be managed with timely treatment to reduce complications.

### **Prevention of Toxoplasmosis During Pregnancy**

Several new approaches to preventing toxoplasmosis during pregnancy have been developed[1]. In 2018, Italian researchers published studies evaluating the effectiveness of prophylactic drug regimens and vaccines for pregnant women. These studies aimed to reduce the risk of toxoplasmosis during pregnancy and mitigate its consequences by incorporating medications and preventive measures[5]. The most dangerous form of toxoplasmosis occurs during the first 12 weeks of pregnancy, as the parasite can severely impair fetal development[24, 12]. Preventive measures are the most important factor in reducing the spread of toxoplasmosis and ensuring no risk to pregnancy. Simple but effective preventive actions, such as avoiding contact with cat feces, properly cooking meat, and consuming clean and well-washed food, play a significant role in preventing the spread of toxoplasmosis. Early detection of toxoplasmosis in pregnant women and its proper treatment provide the opportunity to reduce complications during pregnancy and maintain the health of the baby.

### **Prevention and Precautionary Measures**

Preventative measures are crucial to avoiding toxoplasmosis. These include:

**Sanitary Measures:** Proper disposal of cat feces, thorough cooking of meat, and careful washing of vegetables are essential steps[2].

**Precautions for Pregnant Women:**

Pregnant women should avoid contact with cats and refrain from consuming raw or undercooked meat. Regular screenings for toxoplasmosis during pregnancy are also vital. By adhering to these precautions and ensuring early diagnosis, the risks associated with toxoplasmosis can be significantly reduced[36].

**Immunotherapy and Treatment Approaches**

Notable developments in treatment strategies for toxoplasmosis have emerged over the last decade. From 2013 to 2023, new drugs and treatment protocols have been introduced:

The combination of antimicrobial drugs, particularly pyrimethamine and sulfadiazine, has remained a cornerstone of toxoplasmosis treatment[25]. A 2017 study by researchers at the Cleveland Clinic demonstrated that the addition of leucovorin to this regimen increased the efficacy of the treatment. Despite these advancements, achieving a complete cure for toxoplasmosis remains a complex challenge[18].

A study published in the Journal of Antimicrobial Chemotherapy in 2019 investigated the efficacy of new antibiotics such as atovaquone and clindamycin against toxoplasmosis. These findings have paved the way for developing novel approaches to treat toxoplasmosis, especially in immunocompromised patients[25].

The scientific advancements in understanding toxoplasmosis over the last decade have significantly contributed to improving diagnostic and treatment strategies. These studies have laid the groundwork for future innovations, aiming to mitigate the impact of this parasitic infection more effectively[28, 29].

**Modern Immunological Approaches**

In 2021, researchers from Carnegie Mellon University developed new immunomodulators to study the immune response to toxoplasmosis. Their research proposed innovative methods to strengthen immunity against *Toxoplasma gondii*[13]. These approaches are particularly important for immunocompromised patients, such as those with AIDS, as they enhance the immune system's ability to combat toxoplasmosis, accelerating recovery and improving treatment outcomes[31]

**Conclusion**

Toxoplasmosis is an infectious disease caused primarily by the parasite *Toxoplasma gondii*, which poses a serious risk during pregnancy. The disease can present in mild or asymptomatic forms in many patients, but in pregnant women and individuals with weakened immune systems, the infection often leads to severe complications. The risk of toxoplasmosis during pregnancy affects not only the mother's health but also directly impacts the fetus, as the parasite can be

transmitted to the unborn child, leading to severe neurological and organ-forming disorders such as microcephaly, hydrocephalus, and ocular inflammation. At the same time, more scientific research and large-scale epidemiological studies are needed to reduce the global spread of toxoplasmosis. Improving diagnostic and treatment methods, strengthening preventive measures, and expanding medical knowledge related to the disease are crucial, especially in developing countries, to protect public health.

## REFERENCES

1. Amir, L., et al., "Rubella Immunization and Pregnancy Outcomes: A Systematic Review," *Vaccine*, 2021.DOI: 10.1016/j.vaccine.2021.04.002
2. Bennett, D., et al., "Evaluation of the Impact of Rubella and Toxoplasmosis during Pregnancy," *Journal of Infection and Public Health*, 2020.DOI: 10.1016/j.jiph.2020.02.013
3. Brock, B., & Rappaport, E., "Impact of TORCH Infections on Neonates," *Neonatal Infection Journal*, 2020.DOI: 10.1002/nej.323
4. Cameron, A., et al., "Neonatal Outcomes of Toxoplasmosis and Cytomegalovirus Infection: A Cohort Study," *Pediatric Infectious Disease Journal*, 2022.DOI: 10.1097/INF.0000000000003265
5. Carvalho, F., et al., "Screening for TORCH Infections in Pregnancy: A Global Overview," *The Lancet Infectious Diseases*, 2021.DOI: 10.1016/S1473-3099(21)00477-0
6. Chang, W., et al., "Evaluation of Congenital Toxoplasmosis Diagnosis and Treatment in Neonates," *Pediatric Infectious Disease Journal*, 2021.DOI: 10.1097/INF.0000000000003190
7. Davis, K., et al., "The Role of TORCH Infections in Congenital Malformations," *Clinical Genetics*, 2021.DOI: 10.1111/cge.13791
8. Dixon, M., & Ryan, J., "Clinical Approaches to Managing Cytomegalovirus Infections in Pregnancy," *The Lancet Infectious Diseases*, 2021.DOI: 10.1016/S1473-3099(21)00225-3
9. Evans, L., et al., "Detection and Management of Toxoplasmosis during Pregnancy: A Review of Current Guidelines," *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 2022.DOI: 10.1016/j.ejogrb.2022.05.019
10. Givens, D., et al., "Current Advances in the Diagnosis of Toxoplasmosis in Pregnancy," *Clinical Microbiology Reviews*, 2021.DOI: 10.1128/CMR.00077-20



11. Green, E., et al., "Toxoplasmosis and Congenital Malformations: Insights from Animal Models," *Trends in Parasitology*, 2020.DOI: 10.1016/j.pt.2020.06.010
12. Hall, G., et al., "Cytomegalovirus and Pregnancy: Diagnostic and Treatment Advances," *Clinical Infectious Diseases*, 2021.DOI: 10.1093/cid/ciab228
13. Jones, J. L., et al., "Toxoplasmosis in Pregnancy: Maternal, Fetal, and Neonatal Outcomes," *American Journal of Obstetrics & Gynecology*, 2020.DOI: 10.1016/j.ajog.2020.03.010
14. Keller, E., et al., "Global Impact of TORCH Infections on Maternal and Neonatal Health," *International Journal of Women's Health*, 2021.DOI: 10.2147/IJWH.S318416
15. Kumar, A., & Gupta, P., "Maternal Cytomegalovirus and the Risk to Fetus," *Clinical Infectious Diseases*, 2022.DOI: 10.1093/cid/ciac048
16. Le, V., & Thompson, T., "Strategies for Preventing TORCH Infections during Pregnancy," *The Lancet Infectious Diseases*, 2022.DOI: 10.1016/S1473-3099(22)00101-4
17. López, C., et al., "Toxoplasmosis: A Growing Concern for Maternal Health," *Journal of Clinical Microbiology*, 2021.DOI: 10.1128/JCM.00863-21
18. Maddox, K., & Thomas, C., "Prenatal Management of TORCH Infections: A Clinical Approach," *International Journal of Gynecology & Obstetrics*, 2021.DOI: 10.1002/ijgo.13653
19. Mendez, M., & Jaffe, H., "Advances in the Diagnosis and Treatment of Toxoplasmosis during Pregnancy," *Infectious Disease Clinics of North America*, 2022.DOI: 10.1016/j.idc.2022.04.005
20. Miller, S., & Simms, B., "Prevention of TORCH Infections during Pregnancy," *Prenatal Medicine*, 2020.DOI: 10.1016/j.premed.2020.101232
21. Martinez, J., & Holmes, K., "Rubella in Pregnancy: Risks and Recommendations for Prevention," *Vaccine Research*, 2020.DOI: 10.1016/j.vaccine.2020.06.009
22. Mishra, A., & Patel, R., "Cytomegalovirus Infection: Diagnosis and Treatment in Pregnancy," *Infectious Disease Reviews*, 2021.DOI: 10.1016/j.idr.2021.100026
23. Nguyen, S., et al., "The Effect of Cytomegalovirus on Pregnancy and Its Diagnosis," *Journal of Obstetrics and Gynaecology Research*, 2022.DOI: 10.1111/jog.15335

24. Sachs, L., et al., "The Role of Prenatal Screening for TORCH Infections," *American Journal of Perinatology*, 2021.DOI: 10.1055/s-0041-1732680
25. Shah, R., & Patel, M., "Prevention and Management of Cytomegalovirus during Pregnancy," *Obstetrics & Gynecology Clinics of North America*, 2021. DOI: 10.1016/j.ogc.2021.02.002
26. Singh, S., & Jain, S., "Toxoplasmosis and Pregnancy: Risk, Diagnosis, and Management," *Journal of Maternal-Fetal & Neonatal Medicine*, 2020.DOI: 10.1080/14767058.2020.1771432
27. Scully, C., et al., "TORCH Infections in Pregnancy: What the Clinician Needs to Know," *Obstetrics & Gynecology*, 2021. DOI: 10.1097/AOG.0000000000004472
28. Tiwari, T., & Madsen, C. D., "TORCH Infections and Pregnancy: A Review," *Journal of Obstetrics and Gynaecology*, 2019.DOI: 10.1080/01443615.2019.1674536
29. Williams, E., et al., "Management of Neonatal TORCH Infections: A Review of Current Strategies," *Pediatric Journal of Infection*, 2020.DOI: 10.1016/j.pedid.2020.04.005
30. Wilson, J., et al., "Management of Rubella Infection During Pregnancy: A Systematic Review," *Obstetrical & Gynecological Survey*, 2021.DOI: 10.1097/OGX.0000000000000881
31. Xu, Q., et al., "Toxoplasmosis in Pregnancy: Current Understanding and Management," *Journal of Obstetrics and Gynaecology Research*, 2022.DOI: 10.1111/jog.14676
32. Young, C., et al., "TORCH Infections: Implications for Pregnancy and Neonatal Health," *Journal of Clinical Obstetrics and Gynecology*, 2020.DOI: 10.1016/j.jcog.2020.04.003
33. Zhang, Y., et al., "Evaluation of Rubella in Pregnancy: Current Perspectives and Challenges," *Viral Therapy and Prevention*, 2020.DOI: 10.1016/j.virther.2020.100011
34. Zhou, F., et al., "Cytomegalovirus Infections in Pregnancy: Risk Factors, Diagnosis, and Treatment," *Pediatric Infectious Disease Journal*, 2021.DOI: 10.1097/INF.0000000000002989